$38,965,983

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

biotechactiveONGOING · MOD OF 2020 CONTRACT

WORK BEGAN2020-09-28·LATEST ACTION2026-05-08·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50120C00171_7505_-NONE-_-NONE-

Award description

INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3.

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Development of INV-102 treatment for mustard gas keratopathy, a chemical weapons injury to the eye.

Sub-sectors

pharmaceutical-developmentmedical-countermeasureschemical-defense

Why this matters

Addresses medical countermeasure gap for chemical weapons exposure; supports ASPR preparedness mission for CBRN threats.

Supply-chain signal

Signals demand for specialized ophthalmologic pharmaceutical manufacturing and chemical defense medical countermeasure supply chains.

U.S.–China competition angle

Strengthens U.S. medical defense capabilities against chemical weapons; relevant to asymmetric threat preparedness.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002201.

Period of performance

Start

2020-09-28

End

2028-11-16

Status

activein 912 days

Recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50120C00171_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.